Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
324.99B
Market cap324.99B
Price-Earnings ratio
30.55
Price-Earnings ratio30.55
Dividend yield
1.92%
Dividend yield1.92%
Average volume
2.46M
Average volume2.46M
High today
$164.06
High today$164.06
Low today
$160.42
Low today$160.42
Open price
$162.56
Open price$162.56
Volume
3.15M
Volume3.15M
52 Week high
$170.46
52 Week high$170.46
52 Week low
$122.57
52 Week low$122.57

NVS News

Zacks 1d
All You Need to Know About Novartis Rating Upgrade to Buy

Investors might want to bet on Novartis (NVS Quick QuoteNVS - Free Report) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is ess...

All You Need to Know About Novartis Rating Upgrade to Buy
Zacks 1d
Why Novartis is a Top Momentum Stock for the Long-Term

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways...

Why Novartis is a Top Momentum Stock for the Long-Term
Zacks 4d
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie

Chicago, IL – October 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the l...

The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie

Analyst ratings

57%

of 7 ratings
Buy
57.1%
Hold
42.9%
Sell
0%

More NVS News

TipRanks 4d
Novartis Earnings Call: Core Strength Amid Pipeline Tests

Novartis AG ((NVS)) has held its Q3 earnings call. Read on for the main highlights of the call. Novartis’ latest earnings call struck an upbeat tone, with mana...

Benzinga 4d
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit

Novartis AG (NYSE:NVS) reported mixed third-quarter earnings on Tuesday as the prized Avidity Biosciences deal worth $12 billion cost the company an estimated $...

Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit
Zacks 4d
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss

Swiss pharma giant Novartis AG (NVS Quick QuoteNVS - Free Report) reported third-quarter 2026 core earnings per share (excluding one-time charges) of $2.4...

NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
Investor's Business Daily 4d
Novartis Hikes Income Forecast, But There Were Caveats Within Its Report

Technology Novartis Hikes Income Forecast, But There Were Caveats Within Its Report Licensing Novartis (NVS) stock edged higher early Tuesday after the pharma g...

Novartis Hikes Income Forecast, But There Were Caveats Within Its Report
Zacks 4d
The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP

Chicago, IL – October 27, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the l...

The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP
The Wall Street Journal 5d
Novartis Raises Guidance Despite Trial Setbacks Hitting Profit

Novartis said its net profit result was hit by a $1.9 billion write-down for neuromuscular drug candidate, del-desiran. fabrice coffrini / Agence France-Presse...

Novartis Raises Guidance Despite Trial Setbacks Hitting Profit

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.